New TB drug combo shows promise in early trial
NCT ID NCT04550832
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase IIb trial tested an experimental antibiotic called delpazolid, added to a standard three-drug regimen (bedaquiline, delamanid, moxifloxacin), in 76 adults with newly diagnosed, drug-sensitive pulmonary tuberculosis. The main goals were to check safety and how the drug levels in the body relate to its effects. Results help determine the right dose for future studies, but the trial was not designed to prove a cure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
delpazolid (an experimental antibiotic) combined with bedaquiline, delamanid, and moxifloxacin
What this could lead to
If successful, this could lead to a shorter, more effective treatment regimen for drug-sensitive tuberculosis.
What could go wrong
This is a small, early-phase trial (76 participants) focused on safety and dosing, not on cure rates. The experimental drug is not yet licensed, and side effects or lack of added benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical HIV Research Unit (CHRU) University of the Witwatersrand
Johannesburg, 2092, South Africa
-
Ifakara Health Institute
Bagamoyo, Tanzania
-
Ki'bongoto Infectious Disease Hospital (KIDH) Kilimanjaro Clinical Research Institute (KCRI)
Moshi, Tanzania
-
National Institute for Medical Research (NIMR-MMRC)
Mbeya, Tanzania
-
The Aurum Institute Tembisa Clinical Research Centre
Tembisa, Gauteng, 1632, South Africa